BioNexus Gene Lab (BGLC) Cash & Current Investments (2018 - 2026)

BioNexus Gene Lab's Cash & Current Investments history runs 9 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 89.76% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 89.76% YoY), while the FY2025 annual figure was $4.0 million, down 28.89% from the prior year.
• Cash & Current Investments came in at $4.0 million for Q1 2026 at BioNexus Gene Lab, down from $4.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $6.1 million in Q3 2023 to a low of $1.3 million in Q2 2022.
• A 5-year average of $3.1 million and a median of $2.7 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 320.37% in 2023 and plunged 56.64% in 2024, its largest moves.
• BioNexus Gene Lab's Cash & Current Investments stood at $2.1 million in 2022, then jumped by 113.21% to $4.5 million in 2023, then climbed by 25.75% to $5.7 million in 2024, then slipped by 28.89% to $4.0 million in 2025, then decreased by 1.85% to $4.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.0 million, $4.0 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison